🇺🇸 PTCT — PTC Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

68,12 USD

Máx. histórico

89,55

117 días

Caída desde máximo

-23,93%

Rango 52 semanas

58,80 – 90,87

Variación hoy

+11,89%

Cierre anterior

60,88

Rango de hoy

63,16 – 68,72

Volumen hoy

2.643.738

Peor caída histórica

-94,60%

17/03/2015 → 03/11/2016

Recuperado en 3305 días

Volatilidad anualizada ⓘ

72,99%

Información
Nombre completo
PTC Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
991
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
100,47 USD (puede no estar actualizado)
Primera cotización
20/06/2013
Precio actualizado
hace 17 horas
Sobre la empresa

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to children and adults living with rare disorders in the United States and internationally. The company provides Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and inflammation and ferroptosis platforms, including vatiquinone to treat Friedreich's ataxia. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd., Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. The company has license and collaboration agreement with Novartis Pharmaceuticals Corporation to develop PTC518 Huntington's disease program. It markets Upstaza, a gene therapy with the brand name Kebilidi in the United States. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in Warren, New Jersey.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
22/03/2016 6,15 6,32 6,00 6,23 +1,30% 5,20% 965.000
21/03/2016 5,87 6,32 5,75 6,15 +3,71% 9,74% 1.132.800
18/03/2016 5,60 6,04 5,57 5,93 +7,82% 8,39% 3.307.300
17/03/2016 5,49 5,62 5,30 5,50 +0,36% 5,83% 1.388.200
16/03/2016 5,60 5,73 5,27 5,48 -3,18% 8,21% 1.563.200
15/03/2016 6,22 6,31 5,62 5,66 -10,44% 11,09% 1.555.500
14/03/2016 6,09 6,46 5,95 6,32 +2,76% 8,37% 1.279.300
11/03/2016 5,88 6,17 5,69 6,15 +6,77% 8,16% 1.484.000
10/03/2016 5,99 6,13 5,62 5,76 -2,37% 8,51% 1.383.900
09/03/2016 6,21 6,26 5,83 5,90 -4,22% 6,94% 1.575.300
08/03/2016 6,19 6,42 6,16 6,16 -4,94% 4,20% 1.999.500
07/03/2016 6,24 6,54 5,97 6,48 +6,93% 9,13% 2.528.600
04/03/2016 6,10 6,25 5,85 6,06 -0,66% 6,56% 2.282.400
03/03/2016 6,55 6,80 6,00 6,10 -4,69% 12,21% 3.731.100
02/03/2016 5,75 6,68 5,57 6,40 +15,32% 19,29% 7.896.500
01/03/2016 7,56 7,69 5,29 5,55 -30,45% 31,75% 13.132.800
29/02/2016 7,93 8,57 7,79 7,98 -0,13% 9,84% 6.060.600
26/02/2016 11,51 11,69 7,83 7,99 -29,42% 33,54% 7.719.500
25/02/2016 10,95 12,26 10,52 11,32 +7,71% 15,89% 7.278.300
24/02/2016 10,61 11,47 10,11 10,51 -3,04% 12,81% 6.438.300
23/02/2016 16,13 17,00 10,80 10,84 -61,64% 38,44% 26.582.000
22/02/2016 29,77 29,98 27,76 28,26 -2,01% 7,46% 607.600
19/02/2016 29,16 29,70 27,56 28,84 -1,33% 7,34% 785.500
18/02/2016 29,67 30,23 28,67 29,23 -1,81% 5,26% 676.900
17/02/2016 28,62 30,00 28,09 29,77 +6,47% 6,67% 745.700
16/02/2016 26,20 28,22 25,80 27,96 +9,60% 9,24% 670.900
12/02/2016 24,51 25,61 23,20 25,51 +5,28% 9,83% 571.200
11/02/2016 23,14 24,80 22,67 24,23 +2,11% 9,20% 559.400
10/02/2016 24,24 25,81 23,48 23,73 -0,13% 9,61% 489.700
09/02/2016 22,85 25,62 22,36 23,76 +1,67% 14,27% 515.000